Hey jay, think the holy grail for any speccy, especially the biohealth field is a adequact funding source ..... not 'endless' CR s.
Sad but a fact that many companies have the 'story' but lack the funds or clout to see it thru. If significant revenue is not forth coming the market will value accordingly.
Apart from CR s and Govermment grants think that it makes for a hard slog for a penny stock to see it thru.
What is ultimately needed, if revenue not existent, is a major to see the promise and fund R &D and then distribute thru its existing and established network.
Imagine what Mr Frazer and team could accomplish with his immunotherapies R&D with the backing of a major
Pharma .... the luxury of time and funds.
Remember too there are many 'stories' from many companies, funding for them is finite, perhaps only the best of them with top focused mangerment will make the 'Grand Final'.
